This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, D.-H. Articles by Park, J. Search for Related Content PubMed PubMed Citation Articles by Kim, D.-H. Articles by Park, J.

Hypermethylation of RASSF1A Promoter Is Associated with the Age at Starting Smoking and a Poor Prognosis in Primary Non-Small Cell Lung Cancer¹

Center for Genome Research, Samsung Biomedical Research Institute [D-H. K., J. S. K., Y-I. J., J. P.] and Departments of Thoracic Surgery [Y. M. S.], Division of Pulmonary and Critical Care Medicine [H. K.], and Pathology [J. H.], Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea 135-710, and Department of Molecular Cell Biology, Sungkyunkwan University, School of Medicine, Suwon, Korea 440-746 [J. P.]

Cigarette smoking is the most common cause of lung cancer. The greatest risk of lung cancer is among those who started smoking early in life and continued throughout their lives. However, the molecular mechanisms responsible for the susceptibility to lung cancer in the young smoker are not clear. Recently, several groups have reported that the hypermethylation of CpG islands is associated with exposure to tobacco smoke. We studied the association between the age at starting smoking and hypermethylation of p14, p16, and RASSF1A promoters in 204 primary non-small cell lung cancer patients. We also examined whether hypermethylation of the RASSF1A promoter is an independent prognostic factor. Methylation rates in the 204 samples were detected in 9% for p14, 27% for p16, and 32% for RASSF1A. There was no relationship between the hypermethylation of p14 and p16 and the age at starting smoking. However, hypermethylation of the RASSF1A promoter was found to be significantly associated with the age at starting smoking (P = 0.001). No relationship was found between the methylation status of the RASSF1A promoter and other smoking variables, such as pack-years, smoking status, and the duration of smoking. The age at starting smoking in patients with hypermethylation of RASSF1A was earlier than that of patients without hypermethylation of the RASSF1A promoter (19 ± 8 versus 25 ± 7; P = 0.001). Young smokers who started smoking before age 19 were 4.23 times [95% confidence interval (CI) = 1.03–9.67; P = 0.001] more likely to have hypermethylation of the RASSF1A promoter than smokers who started smoking after the age of 19. Furthermore, hypermethylation of the RASSF1A promoter was found to be associated with a poor prognosis in non-small cell lung cancer patients at stages 1 and 2 (P = 0.02 and 0.01, respectively; Log-rank test). The hazard of failure was 3.27 times higher for patients with hypermethylation of the RASSF1A promoter than for those without hypermethylation of the RASSF1A promoter (95% CI = 1.42–8.71; P = 0.01). Young smokers who started the habit before the age of 19 also had a poorer prognosis than those who started after the age of 19 (hazard ratio = 2.14, 95% CI = 1.22–9.11; P = 0.02). Our results suggest that starting cigarette smoking at an early age is associated with hypermethylation of the RASSF1A promoter and that hypermethylation of the RASSF1A promoter may be an independent prognostic factor in primary non-small cell lung cancer.

This article has been cited by other articles:

				T. Vaissiere, R. J. Hung, D. Zaridze, A. Moukeria, C. Cuenin, V. Fasolo, G. Ferro, A. Paliwal, P. Hainaut, P. Brennan, et al. Quantitative Analysis of DNA Methylation Profiles in Lung Cancer Identifies Aberrant DNA Methylation of Specific Genes and Its Association with Gender and Cancer Risk Factors Cancer Res., January 1, 2009; 69(1): 243 - 252. [Abstract] [Full Text] [PDF]

				E. M. Wolff, G. Liang, C. C. Cortez, Y. C. Tsai, J. E. Castelao, V. K. Cortessis, D. D. Tsao-Wei, S. Groshen, and P. A. Jones RUNX3 Methylation Reveals that Bladder Tumors Are Older in Patients with a History of Smoking Cancer Res., August 1, 2008; 68(15): 6208 - 6214. [Abstract] [Full Text] [PDF]

				Q. Feng, S. E. Hawes, J. E. Stern, L. Wiens, H. Lu, Z. M. Dong, C. D. Jordan, N. B. Kiviat, and H. Vesselle DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 645 - 654. [Abstract] [Full Text] [PDF]

				J. Gu, D. Berman, C. Lu, I. I. Wistuba, J. A. Roth, M. Frazier, M. R. Spitz, and X. Wu Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., December 15, 2006; 12(24): 7329 - 7338. [Abstract] [Full Text] [PDF]

				C. J. Marsit, M. R. Karagas, H. Danaee, M. Liu, A. Andrew, A. Schned, H. H. Nelson, and K. T. Kelsey Carcinogen exposure and gene promoter hypermethylation in bladder cancer Carcinogenesis, January 1, 2006; 27(1): 112 - 116. [Abstract] [Full Text] [PDF]

				Y. T. Kim, S. J. Park, S. H. Lee, H. J. Kang, S. Hahn, C. H. Kang, S. W. Sung, and J. H. Kim Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1378 - 1378. [Abstract] [Full Text] [PDF]

				M. Prochazka, P. Hall, G. Gagliardi, F. Granath, B. N. Nilsson, P. G. Shields, M. Tennis, and K. Czene Ionizing Radiation and Tobacco Use Increases the Risk of a Subsequent Lung Carcinoma in Women With Breast Cancer: Case-Only Design J. Clin. Oncol., October 20, 2005; 23(30): 7467 - 7474. [Abstract] [Full Text] [PDF]

				M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]

				A. J. Alberg, M. V. Brock, and J. M. Samet Epidemiology of Lung Cancer: Looking to the Future J. Clin. Oncol., May 10, 2005; 23(14): 3175 - 3185. [Abstract] [Full Text] [PDF]

				A. Agathanggelou, W. N. Cooper, and F. Latif Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers Cancer Res., May 1, 2005; 65(9): 3497 - 3508. [Abstract] [Full Text] [PDF]

				C. J. Marsit, M. Hasegawa, T. Hirao, D.-H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson, and K. T. Kelsey Loss of Heterozygosity of Chromosome 3p21 Is Associated with Mutant TP53 and Better Patient Survival in Non-Small-Cell Lung Cancer Cancer Res., December 1, 2004; 64(23): 8702 - 8707. [Abstract] [Full Text] [PDF]

				M. Guo, Y. Akiyama, M. G. House, C. M. Hooker, E. Heath, E. Gabrielson, S. C. Yang, Y. Han, S. B. Baylin, J. G. Herman, et al. Hypermethylation of the GATA Genes in Lung Cancer Clin. Cancer Res., December 1, 2004; 10(23): 7917 - 7924. [Abstract] [Full Text] [PDF]

				P. J. Mazzone, T. Mekhail, and A. C. Arroliga Is Lung Cancer in the Nonsmoker a Different Disease? Chest, August 1, 2004; 126(2): 326 - 329. [Full Text] [PDF]

				H.-S. Hsu, Y.-C. Wang, R.-C. Tseng, J.-W. Chang, J.-T. Chen, C.-M. Shih, C.-Y. Chen, and Y.-C. Wang CpG Island Methylation Is Responsible for p14ARF Inactivation and Inversely Correlates with p53 Overexpression in Resected Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4734 - 4741. [Abstract] [Full Text] [PDF]

				S. A. Belinsky, D. M. Klinge, K. C. Liechty, T. H. March, T. Kang, F. D. Gilliland, N. Sotnic, G. Adamova, G. Rusinova, and V. Telnov Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma Carcinogenesis, June 1, 2004; 25(6): 1063 - 1067. [Abstract] [Full Text] [PDF]

				S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF]